Showing results (411-420 of 513) with videos related to

Sort By:
Pageof 52
International Journal of Radiation Oncology, Biology, Physics|February 12, 2022
Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 TherapyKyung Hwan Kim, Hongryull Pyo, Hoyoung Lee, et al.
JCO Precision Oncology|July 23, 2025
Deep-Learning Model for Real-Time Prediction of Recurrence in Early-Stage Non-Small Cell Lung Cancer: A Multimodal Approach (RADAR CARE Study)Hyun Ae Jung, Daehwan Lee, Boram Park, et al.
Oncotarget|January 13, 2016
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)Ji Yun Lee, Xu Qing, Wei Xiumin, et al.
The Journal of Molecular Diagnostics : JMD|December 19, 2012
Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancerMaruja E Lira, Tae Min Kim, Donghui Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancerJinny Park, Byung Bae Park, Jee Youn Kim, et al.
Leukemia & Lymphoma|August 23, 2006
CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluationYeon Hee Park, Se-Hoon Lee, Won Seog Kim, et al.
Medical Oncology (Northwood, London, England)|April 24, 2008
Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphomaWon Seog Kim, Yeon Hee Park, Se-Hoon Lee, et al.
Oncotarget|December 2, 2016
The implication of FLT3 amplification for FLT targeted therapeutics in solid tumorsSung Hee Lim, Sun-Young Kim, Kyung Kim, et al.
Cancer Research and Treatment|May 2, 2024
Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 TrialJunghoon Shin, Sehhoon Park, Kyung Hwan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|February 14, 2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysisHidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, et al.
Pageof 52